BioPorto A/S has announced the appointment of Anthony Pare as its new Chief Executive Officer (CEO). Anthony (Tony) Pare will join BioPorto directly from T2 Biosystems, where he served as the Chief Commercial Officer and presided over several successful product launches. He will start in BioPorto by mid-November 2021. Prior to T2 Biosystems, Anthony Pare served as Chief Commercial Officer at Hemanext (US), and in various commercial and business development leadership roles at Haemonetics (US). As previously announced, outgoing CEO Peter Mørch Eriksen will remain at BioPorto in a full-time advisory role until January 2022.